Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Coadministration of drugs is common in the pharmacologic treatment of dyslipidemia, with
statins and ezetimibe generally constituting the medication of choice. By acting at different
levels, the combination of these drugs allows the therapeutic objective to be achieved.
However, it is not known how these drugs qualitatively affect the composition of lipoprotein
subfractions, which differ in size and atherogenic potential. The investigators set out to
evaluate this effect as well as their effects on inflammatory, oxidative stress and
endothelial function parameters.
Phase:
N/A
Details
Lead Sponsor:
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Treatments:
Ezetimibe Ezetimibe, Simvastatin Drug Combination Simvastatin